CALC · CalciMedica, Inc. · Executive Compensation
$1.07
+0.05 (+4.41%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company's current operating plans, management believes its cash and cash equivalents may not be sufficient to fund its operations for a period of one year following the issuance of these financial statements. As a result, there is substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Market Cap
$7.27M
Shares
6.83M
Volume · Oct 20
41.81K
Avg daily vol (35 sessions)
75.7K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| A. Rachel Leheny | Chief Executive Officer | $895,410 |
| Sudarshan Hebbar | Chief Medical Officer | $763,315 |
| Eric W. Roberts | Vice Chairman and Chief Business Officer | $703,558 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| A. Rachel Leheny | Chief Executive Officer | $1,657,842 |
| Sudarshan Hebbar | Chief Medical Officer | $1,348,571 |
| Eric W. Roberts | Vice Chairman and Chief Business Officer | $1,295,263 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Frederic Guerard | Former Chief Executive Officer | $2,104,693 |
| Robert S. Breuil | Former Chief Financial Officer | $1,163,622 |
| Parisa Zamiri | Former Chief Medical Officer | $1,056,448 |
| A. Rachel Leheny | Chief Executive Officer | $1,012,835 |
| Eric W. Roberts | Chief Business Officer | $815,759 |
| Kenneth A. Stauderman | Chief Scientific Officer | $696,859 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Frederic Guerard | Former Chief Executive Officer | $2,201,203 |
| Parisa Zamiri | Former Chief Medical Officer | $1,125,868 |
| Robert S. Breuil | Former Chief Financial Officer | $1,096,959 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Frederic Guerard | Pharm.D. Chief Executive Officer | $4,405,460 |
| Parisa Zamiri | M.D., Ph.D. Chief Medical Officer | $1,817,535 |
| Robert S. Breuil | Chief Financial Officer | $1,801,834 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Frederic Guerard | Chief Executive Officer | $4,221,840 |
| Robert S. Breuil | Chief Financial Officer | $3,955,361 |
| Parisa Zamiri | Chief Medical Officer | $1,610,840 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Frederic Guerard | Chief Executive Officer | $989,223 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Robert N. Wilson | Class III director | Appointed | 2026-08-20 |
| Allan Shaw | Class III director | Appointed | 2026-08-20 |
| Evgeny Zaytsev, M.D., Ph.D. | Class I director | Appointed | 2026-07-07 |
| Frederic Guerard, Pharm.D. | Class II director | Appointed | 2025-06-27 |
| Eric W. Roberts | Class II director | Appointed | 2025-06-27 |
| A. Rachel Leheny, Ph.D. | Class II director | Appointed | 2025-06-27 |
| Alan Glicklich, M.D. | Class I director | Appointed | 2025-01-14 |
| Eric Bjerkholt | member of the board of directors and Chair and a member of the audit committee of the Board | Resigned | 2025-01-14 |
| Stephen Bardin | Chief Financial Officer | Appointed | 2024-11-08 |
| Stephen Bardin | principal accounting officer | Appointed | 2024-11-08 |
| Dan Geffken | principal accounting officer | Resigned | 2024-11-08 |
| Dan Geffken | interim Chief Financial Officer | Resigned | 2024-11-08 |
| Fred Middleton | Class I director | Appointed | 2024-08-27 |
| Eric Bjerkholt | Class I director | Appointed | 2024-08-27 |
| Eric Roberts | member of the Company’s Board of Directors | Appointed | 2023-03-22 |
| Eric Roberts | Vice Chairman of the Board and the Chairman of the Strategic Transactions and Finance Committee of the Board | Appointed | 2023-03-22 |
| Ann Rachel Leheny | Chief Executive Officer | Appointed | 2023-03-22 |
| Frederic Guerard, Pharm.D. | Class II Director | Appointed | 2023-03-22 |
| Allan Shaw | Class III Director | Appointed | 2023-03-22 |
| Fred Middleton | Class I Director | Appointed | 2023-03-22 |
| Robert N. Wilson | Chair of the Board and Class III Director | Appointed | 2023-03-22 |
| Eric W. Roberts | Class II Director | Appointed | 2023-03-22 |
| Kenneth A. Stauderman, Ph.D. | Chief Scientific Officer | Appointed | 2023-03-22 |
| Eric W. Roberts | Chief Business Officer | Appointed | 2023-03-22 |
| Daniel Geffken, MBA | Interim Chief Financial Officer | Appointed | 2023-03-22 |
Leadership
- A. Rachel Leheny CEO, Board Member
- A. Rachel Leheny, Ph.D. CEO, Board Member
- Ann Rachel Leheny CEO
- Ann Rachel Leheny, Ph.D. CEO
- Eric W. Roberts Chairman
- Robert N. Wilson Chairman, Board Member
- Daniel Geffken, MBA CFO, Chief Accounting Officer
- Stephen Bardin CFO, Chief Accounting Officer
- Michael J. Dunn COO
- Michael J. Dunn, MBA COO
- Alan Glicklich, M.D. Board Member
- Allan Shaw Board Member
- Eric Roberts Board Member
- Evgeny Zaytsev, M.D., Ph.D. Board Member
- Fred Middleton Board Member
- Frederic Guerard, Pharm.D. Board Member